Jeffrey V. Poulton, EVP, Chief Financial Officer at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 2,780 shares at $353.95 ($1.0M) on 2026-01-12, disclosed to the SEC on 2026-01-14.
Open-market sale of $1.0M ALNY by EVP, Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $353.95 | 72 | $25K | 2.5% |
| 2 | $355.16 | 78 | $28K | 2.7% |
| 3 | $356.09 | 76 | $27K | 2.7% |
| 4 | $357.17 | 176 | $63K | 6.2% |
| 5 | $358.18 | 226 | $81K | 8.0% |
| 6 | $359.14 | 156 |
| $56K |
| 5.6% |
| 7 | $360.22 | 284 | $102K | 10.1% |
| 8 | $361.45 | 181 | $65K | 6.5% |
| 9 | $362.38 | 135 | $49K | 4.8% |
| 10 | $363.55 | 87 | $32K | 3.1% |
| 11 | $364.83 | 365 | $133K | 13.2% |
| 12 | $365.56 | 405 | $148K | 14.7% |
| 13 | $366.41 | 92 | $34K | 3.3% |
| 14 | $367.40 | 76 | $28K | 2.8% |
| 15 | $368.62 | 170 | $63K | 6.2% |
| 16 | $369.48 | 73 | $27K | 2.7% |
| 17 | $370.87 | 36 | $13K | 1.3% |
| 18 | $372.46 | 6 | $2K | 0.2% |
| 19 | $374.44 | 25 | $9K | 0.9% |
| 20 | $375.65 | 34 | $13K | 1.3% |
| 21 | $377.82 | 27 | $10K | 1.0% |
| Total | $362.87 avg | 2,780 | $1.0M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2025-10-03 | $3.4M | — | Filing → |
| ALNY | SELL | 2025-08-19 | $2.0M | — | Filing → |